Pharmaceutical giant H. Lundbeck was fined by the European Commission just last year for a pay-for-delay scheme, but now the company is facing antitrust scrutiny from its home country of Denmark.
Reports say H. Lundbeck, which was fined last year by the Commission for paying to have a generic form of its antidepressant Celexa from entering the market, is now under fire by various healthcare providers seeking counsel by the attorney general over whether they can pursue claims against the firm.
This time, say reports, H. Lundbeck is in a spat with generic drug maker Actavis regarding the antidepressant Cipralex. While Actavis argues H. Lundbeck is hampering competition, H. Lundbeck is accusing Actavis of violating its patents.
The feud comes after European Commission fined H. Lundbeck nearly $200 million for the so-called pay-for-delay scheme in 2013.
Full Content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI